NCT05088226RecruitingPhase 2
Ruxolitinib and Chidamide Intensified Bu/CY Conditioning Regimen
Ruxolitinib and Chidamide Intensified Bu/CY Conditioning Regimen for Patients With Acute B Cell Lymphoblast Leukemia Underwenting Haploidenticl Peripheral Blood Stem Cell Transplantation
Source: ClinicalTrials.gov · Last updated 23 Apr 2026
Brief summary (registry, in English)
The purpose of this study is to determine the efficacy and safety of Ruxolitinib and Chidamide intensified conditioning regimen in patients with Acute B cell Lymphoblast leukemia Underwenting Haploidenticl Peripheral blood Stem Cell Transplantation.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- First submitted
- 25 May 2021
- Start date
- 1 Dec 2021
- Primary completion date
- 1 Jun 2030
- Lead sponsor
- Chinese PLA General Hospital
- NCT number
- NCT05088226
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 50
- From 1 Dec 2021 to the primary completion date, 1 Jun 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with mental illness or other states unable to comply with the protocol;
Other
- pregnant women;
- ALL patients with Ph positive;
Who the study is looking for
- high risk acute B cell lymphoblastic leukemia with the indications for allogeneic transplantation;
- Have matched sibling donors, ≥8/10 HLA matched unrelated donors or haploidentical donors
- All patients should aged 12 to 65 years;
- Liver function: ALT and AST≤2.5 times the upper limit of normal , bilirubin≤2 times the upper limit of normal;
- Renal function: creatinine ≤the upper limit of normal;
- Patients without any uncontrolled infections , without organ dysfunction or without severe mental illness;
- Eastern Cooperative Oncology Group (ECOG) performance status ≤2;
- Have signed informed consent.
Age in the registry: 12 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Chinese PLA General Hospital Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.